Warfarin Underuse for Nonvalvular Atrial Fibrillation: How to Adjust Our Aims?
Atrial fibrillation (AF) is the most common arrhythmia in clinical practice; its prevalence increases substantially with age, representing a growing epidemic with substantial effects on mortality and morbidity . The more recent epidemiological data come from a large cross-sectional study in adults in California involving a population of 1.89 million . The prevalence of AF was 0.95%, increasing from 0.1% among adults younger than 55 years to 9.0% in persons aged 80 years or older. The authors estimate that approximately 2.3 million adults in the USA currently have AF and project that this will increase to more than 5.6 million by the year 2050, with more than 50% of affected individuals aged 80 years or older. In Italy it is estimated that there are about 500,000 cases of AF at present, with 60,000 new cases per year.
KeywordsAtrial Fibrillation Stroke Prevention Atrial Fibrillation Patient Antithrombotic Therapy High Risk Factor
Unable to display preview. Download preview PDF.
- 7.Hart RG, Pearce LA, McBride R et al, on behalf of the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators (1999) Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation. Analysis of 2012 participants in the SPAF I-III clinical trials. Stroke 30:1223–1229PubMedCrossRefGoogle Scholar
- 10.Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE (2001) Antithrombotic therapy in atrial fibrillation. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest 119 [Suppl]:194S–206SGoogle Scholar
- 12.Di Pasquale G, Cerè E, Biancoli S et al (2002) Antiplatelet agents for prevention of thromboembolism in atrial fibrillation: when, why, and which one? In: Raviele A (ed) Cardiac arrhythmias 2001. Springer-Verlag Italia, Milan, pp 422–435Google Scholar
- 23.Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori AG (2001) Effect of computeraided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated Program for Oral Anticoagulated Treatment). Haematologica 86:1060–1070PubMedGoogle Scholar